Tecentriq (atezolizumab) / Roche 
Welcome,         Profile    Billing    Logout  
 31 Diseases   517 Trials   517 Trials   19434 News 
701 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NCT06098898: Safety and Efficacy of NK510 to Treat Gastric Cancer

Enrolling by invitation
1
9
RoW
NK510, Tislelizumab，atezolizumab or Trastuzumab
Base Therapeutics (Shanghai) Co., Ltd., Shanghai 10th People's Hospital
Gastric Cancer
11/24
11/24
NCT04161755: Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Active, not recruiting
1
29
US
Atezolizumab, RO7198457, mFOLFIRINOX
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Pancreatic Cancer
11/24
11/24
NCT05053737: Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

Suspended
1
11
US
Atezolizumab, MPDL3280A, RG7446, Tecentriq, Stereotactic Body Radiation Therapy, SBRT
University of Colorado, Denver, Genentech, Inc.
Squamous Cell Carcinoma of Head and Neck
11/23
11/24
NCT04449874: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Recruiting
1
498
Europe, Canada, US, RoW
GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib
Genentech, Inc.
Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
11/24
11/24
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Active, not recruiting
1
60
Europe, US
VB10.NEO, Atezolizumab, Tecentriq
Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS
Solid Tumors, Adult
12/24
12/24
NCT05085496: Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Recruiting
1
12
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
City of Hope Medical Center, Genentech, Inc., National Cancer Institute (NCI)
Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
12/24
12/24
IMMUNOs-SBRT, NCT05259319: Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan

Recruiting
1
92
Europe
Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ], Tiragolumab, Stereotactic body radiation therapy (SBRT)
Centre Georges Francois Leclerc
Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer
12/24
12/24
DEHART, NCT04477759: Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer

Active, not recruiting
1
18
US
50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy, Atezolizumab, Tecentriq
Medical College of Wisconsin, Genentech, Inc., National Cancer Institute (NCI)
Head and Neck Neoplasm
04/24
04/25
NCT04857684: SBRT + Atezolizumab + Bevacizumab in Resectable HCC

Recruiting
1
20
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Stereotactic Beam Radiation Therapy (SBRT), Radiation Therapy
Massachusetts General Hospital, Genentech, Inc.
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
12/24
12/25
NCT05488522: SBRT With Atezo/Bev for HCC

Recruiting
1
18
US
SBRT + atezolizumab and bevacizumab
Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma
12/24
12/26
NCT05542407: ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting
1
58
US
Atezolizumab, ONC201
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc., Oncoceutics, Inc.
Endometrial Cancer, Metastasis
01/25
01/25
INTERCEPT-H3, NCT04808245: A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

Recruiting
1
15
Europe
Tecentriq 1200 MG in 20 ML Injection, Atezolizumab, H3K27M peptide vaccine, Imiquimod (5%), Aldara
German Cancer Research Center, Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid
Newly Diagnosed H3-mutated Glioma
03/25
03/25
NCT05487235: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
232
Europe, Canada, US, RoW
GDC-1971, RO7517834, RLY-1971, Atezolizumab, RO5541267, Omeprazole
Genentech, Inc.
Advanced Solid Tumors, Metastatic Solid Tumors
05/25
05/25
NCT05581004: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
395
Europe, Canada, US, RoW
RO7502175, Atezolizumab
Genentech, Inc.
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
07/25
10/25
DAREON-8, NCT06077500: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Recruiting
1
60
Europe, Japan
BI 764532, Carboplatin, Etoposide, Atezolizumab, Durvalumab, Cisplatin
Boehringer Ingelheim
Small Cell Lung Carcinoma (SCLC)
08/25
06/26
NCT05334329: Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Active, not recruiting
1
6
US
Antineoplastic Immune Cell, Anti-cancer Immune Cell, Antineoplastic Immune Cells, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa
City of Hope Medical Center, National Cancer Institute (NCI), CytoImmune Therapeutics
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
09/25
09/25
Intrinsic, NCT04929223: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Active, not recruiting
1
422
Europe, Canada, US, RoW
Inavolisib, Bevacizumab, Avastin, Cetuximab, Atezolizumab, Tecentriq, Tiragolumab, SY-5609, Divarasib, GDC-6036, FOLFOX, FOLFIRI
Hoffmann-La Roche
Metastatic Colorectal Cancer
09/25
04/26
NCT06066138: A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Not yet recruiting
1
40
US
Atezolizumab
National Cancer Institute (NCI)
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
11/25
11/26
NCT04020809: Neoadjuvant Atezolizumab in Cutaneous Melanoma

Recruiting
1
20
US
Atezolizumab, Tecentriq
The Methodist Hospital Research Institute, Genentech, Inc.
Cutaneous Melanoma
12/25
12/25
DeLLphi-303, NCT05361395: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Recruiting
1
340
Europe, Canada, Japan, US, RoW
Tarlatamab, AMG 757, Carboplatin, Etoposide, Atezolizumab, Tecentriq, Durvalumab
Amgen
Extensive Stage Small Cell Lung Cancer
01/27
01/27
NCT05867121: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
120
Europe, Japan, US, RoW
RO7496353, SOF 10, Atezolizumab, RO554126 7; Tecentriq, Capecitabine, S-1, Tegafur/Gimeracil/Oteracil potassium, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
Genentech, Inc., Chugai Pharmaceutical Co.
Metastatic Solid Tumor, Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
12/25
12/25
IMPRINTER, NCT04432207: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Active, not recruiting
1
24
US, RoW
IMU-201 (administered as PD1-Vaxx) - Regimen 1, PD1-Vaxx, APi2568, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3, Atezolizumab, TECENTRIQ, Standard of care chemotherapy
Imugene Limited
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
02/26
03/26
NCT04560972: LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

Recruiting
1
21
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Protein Phosphatase 2A Inhibitor LB-100, LB-100, PP2A Inhibitor LB-100
City of Hope Medical Center, National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma
03/26
03/26
NCT05097911: Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

Recruiting
1
33
RoW
MTL-CEBPA, Atezolizumab, Bevacizumab
National University Hospital, Singapore
Advanced Hepatocellular Carcinoma
04/26
04/27
NCT05515627: Atezolizumab for Idiopathic Pulmonary Fibrosis

Recruiting
1
24
US
Atezolizumab
Cedars-Sinai Medical Center, Genentech, Inc.
Idiopathic Pulmonary Fibrosis
04/26
04/26
NCT04303858: A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

Active, not recruiting
1
189
Europe, Canada
Eciskafusp Alfa, RO7284755, Atezolizumab, Tecentriq
Hoffmann-La Roche
Solid Tumors
11/26
05/27
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
12/26
12/27
CoLBAt, NCT06012734: LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients

Not yet recruiting
1
37
NA
LB-100, PP2A inhibitor LB-100, Atezolizumab, Tecentriq
The Netherlands Cancer Institute
Metastatic Microsatellite-stable Colorectal Cancer
07/26
07/26
NCT05423210: Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

Recruiting
1
12
US
Atezolizumab + FSRT radiation
Stony Brook University, Genentech, Inc.
Glioblastoma Multiforme
08/26
08/26
NCT04857138: A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

Completed
1
80
Europe, RoW
RO7300490, Atezolizumab
Hoffmann-La Roche
Solid Tumors
01/24
01/24
NCT05092373: Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Recruiting
1
43
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
M.D. Anderson Cancer Center
Advanced Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Abdominal Neoplasm, Advanced Malignant Female Reproductive System Neoplasm, Advanced Malignant Thoracic Neoplasm, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Malignant Abdominal Neoplasm, Malignant Solid Neoplasm, Metastatic Breast Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Abdominal Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Malignant Thoracic Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Renal Cell Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
09/26
09/26
FusionVAC22, NCT05937295: _01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition

Recruiting
1
20
Europe
Fusion-VAC-XS15
University Hospital Tuebingen
Fibrolamellar Hepatocellular Carcinoma
09/26
01/27
NCT05907980: A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Recruiting
1
219
Japan, US
ROSE12, Atezolizumab
Chugai Pharmaceutical
Solid Tumor
12/26
12/26
NCT06031441: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
250
Canada, US, RoW
RO7566802, Atezolizumab, Tecentriq®
Genentech, Inc.
Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
12/26
12/26
NCT05878691: A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Recruiting
1
320
US, RoW
GRC 54276, GRC 54276 + Pembrolizumab, GRC 54276 + Atezolizumab
Glenmark Specialty S.A.
Advanced Solid Tumor, Lymphoma
07/27
07/27
FUDAN-BLCA-01, NCT06169904: B7-Family Score in Urothelial Carcinoma

Completed
N/A
215
NA
Cisplatin injection, Atezolizumab injection
Shanghai Zhongshan Hospital, Fudan University, Shanghai Jiao Tong University School of Medicine
Urothelial Carcinoma
08/20
11/22
RSR-HCC-2019-001, NCT06261138: Survival Analysis: TACE vs. Combination Therapy in HCC

Completed
N/A
279
RoW
Transarterial chemoembolization, TACE, Systemic treatment
Zhejiang University
Hepatocellular Carcinoma
03/23
10/23
NCT02453984: MPDL3280A-imaging-IST-UMCG

Active, not recruiting
N/A
45
Europe
89Zr-MPDL-3280A-PET scans
University Medical Center Groningen
Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression
11/20
06/24
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting
N/A
240
RoW
Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab
Sun Yat-sen University
Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
12/24
12/24
ABCHCaen, NCT06416683: Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma

Completed
N/A
109
Europe
University Hospital, Caen
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
06/23
01/24
NCT06199297: Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma

Completed
N/A
188
RoW
Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
Sun Yat-sen University
Hepatocellular Carcinoma
07/23
07/23
CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

Recruiting
N/A
100
RoW
drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1
Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC)
Cholangiocarcinoma Non-resectable
12/24
06/25
NCT03850028 / 2017-003511-20: Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Withdrawn
N/A
20
Europe
89Zr-atezolizumab PET scans
University Medical Center Groningen, Amsterdam UMC, location VUmc, Stichting Hemato-Oncologie voor Volwassenen Nederland, Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
05/22
05/22
ChiCTR2100052788: a real world study about efficacy and safety of atezolizumab plus chemotherapy in extensive stage small cell lung cancer

Recruiting
N/A
 
Subject to standard treatment regimen of atezolizumab + carboplatin/cisplatin + etoposide ;Standard chemotherapy regimen of carboplatin/cisplatin + etoposide
Beijing Cancer Hospital; Beijing Cancer Hospital, Beijing Hengji Health Management Development Foundation
small cell lung cancer (SCLC)
 
 
CHANCE001, NCT04975932: Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study

Completed
N/A
826
RoW
TACE+ICIs, TACE
Zhongda Hospital
Hepatocellular Carcinoma
05/22
02/23
NCT03035890: Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

Completed
N/A
35
US
Radiation, Hypofractionated Radiation, Immuno-Therapeutic Agent, Immunotherapy
West Virginia University, West Virginia Clinical and Translational Science Institute
Non Small Cell Lung Cancer Metastatic
06/22
06/22
NCT04639284: Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Recruiting
N/A
200
RoW
Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
07/22
07/23
ChiCTR2200061793: Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study

Completed
N/A
30
 
None
The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University; The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University, Self-raised
hepatocellular carcinoma complicated with portal vein tumor thrombus
 
 
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
NCT04862949: Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Completed
N/A
124
RoW
Atezolizumab plus bevacizumab
CHA University, Hoffmann-La Roche
Advanced Hepatocellular Carcinoma
12/22
03/23
NCT04869501: Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

No Longer Available
N/A
US
TJ004309, Atezolizumab, Tecentriq
I-Mab Biopharma US Limited
Cancer
 
 
J-TAIL-2, NCT04501497: Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer

Completed
N/A
1221
Japan
Chugai Pharmaceutical, Japan Lung Cancer Society
Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
02/23
02/23
NCT03559647: The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Completed
N/A
358
Europe
Atezolizumab
Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
08/23
08/23
CHANCE2201, NCT05332821: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

Recruiting
N/A
474
RoW
PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
Zhongda Hospital
Hepatocellular Carcinoma
08/23
08/23
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

Recruiting
N/A
220
RoW
PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
Zhongda Hospital
Hepatocellular Carcinoma
08/23
09/23
EXIT, NCT05934214: EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database

Completed
N/A
141630
Europe
Immune checkpoint inhibitor
Groupe Hospitalier Pitie-Salpetriere, Institut Curie
Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis
12/23
02/24
AUTENTIC, NCT03868046: Autoantibodies in Treatment With Immune Checkpoint Inhibitors

Recruiting
N/A
221
Europe
Treatment with immune checkpoint inhibitors., Blood tests.
Hospital Universitario Araba, Hospital de Basurto, Hospital Donostia, Complejo Hospitalario de Navarra, Hospital Galdakao-Usansolo
Cancer, Metastatic Cancer, Solid Organ Cancer
10/23
12/23
IBFIC, NCT05260606: Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer

Recruiting
N/A
100
RoW
F-18 FDG PET/CT
Samsung Medical Center
Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors
12/25
12/25
PETNEC, NCT04564482: PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer

Recruiting
N/A
20
Europe
CRT, SCPRT, CROSS Protocol, PD-L1 PET
Johannes Laengle, MD, PhD, Christian Doppler Laboratory Applied Metabolomics
Rectal Cancer Stage, Oesophageal Cancer
12/25
06/26
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study

Not yet recruiting
N/A
200
NA
TACE, Atezolizumab, Bevacizumab
Zhongda Hospital
HCC
12/23
06/24
NCT04680598: Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

Recruiting
N/A
800
RoW
ICI, Antiviral Prophylaxis
Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital, ZhongShan People 's Hospital
Hepatocellular Carcinoma
12/23
12/23
NCT04924374: Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

Recruiting
N/A
20
Europe
Microbiota Transplant plus anti PD1 therapy, anti PD1 therapy Pembrolizumab, Nivolizumab, Atezolizumab, anti PD1 therapy, Pembrolizumab, Nivolizumab, Atezolizumab
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Lung Cancer
12/23
07/24
NCT05173298: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Recruiting
N/A
100
RoW
atezolizumab plus bevacizumab
CHA University, Boryung Pharmaceutical Co., Ltd
Advanced Hepatocellular Carcinoma
07/24
12/24
TACE-TKI-ICI, NCT05717738: Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga
Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd.
Hepatocellular Carcinoma Non-resectable
12/23
12/24
NCT06205732: A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

Recruiting
N/A
100
RoW
Immunotherapy, targeted therapy.
Qianfoshan Hospital
Carcinoma, Hepatocellular
12/24
12/24
NCT06244446: Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.

Not yet recruiting
N/A
40
RoW
No intervention
Institute of Liver and Biliary Sciences, India
Advanced Hepatocellular Carcinoma
01/25
01/25
ISABELLA, NCT05402059: Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice

Recruiting
N/A
1570
RoW
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
MelanomaPRO, Russia
Melanoma, Melanoma (Skin), Melanoma, Uveal, Melanoma Stage IV, Melanoma Stage III, Melanoma, Stage II, Melanoma in Situ, Melanoma, Ocular
04/24
04/25
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor
Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University
Hepatocellular Carcinoma Non-resectable
04/24
12/24
NCT05763277: Ate-Bev Early Response Prediction Model in Advanced HCC

Recruiting
N/A
170
RoW
Early response evaluation
Seoul National University Hospital
Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation
05/24
05/25
NCT04465942: Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Recruiting
N/A
300
Europe
(chemo)immunotherapy, cisplatinum, carboplatinum, pemetrexed, paclitaxel, pembrolizumab, nivolumab, atezolizumab
European Lung Cancer Working Party
Carcinoma, Non-Small-Cell Lung, Immunotherapy
06/24
06/25
NCT05287464: International Multicentric Study ARON-1

Recruiting
N/A
1220
Europe
pembrolizumab plus axitinib, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, nivolumab plus ipilimumab, avelumab plus axitinib, atezolizumab plus bevacizumab
Hospital of Macerata
Metastatic Renal Cell Carcinoma (mRCC)
06/24
12/24
NCT06434480: SBRT in HCC With Oligoprogression on Atezo-Bev

Recruiting
N/A
30
RoW
Stereotactic Body Radiation Therapy (SBRT)
Chinese University of Hong Kong
HCC
03/27
03/28
MITRE, NCT04107168: Microbiome Immunotherapy Toxicity and Response Evaluation

Recruiting
N/A
1800
Europe
Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin
CCTU- Cancer Theme, Microbiotica Ltd
Melanoma, Renal Cancer, Lung Cancer
07/24
07/25
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
N/A
300
Europe
Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab
University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza
Non-small Cell Lung Cancer
11/24
11/24
NCT05197504: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

Recruiting
N/A
100
RoW
atezolizumab plus bevacizumab
CHA University
Hepatocellular Carcinoma
12/24
12/24
ImmunoXXL, NCT05879328: The Study

Recruiting
N/A
12
Europe
Liver Transplantation
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma
12/24
12/24
JOCARDITE, NCT04294771: JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

Recruiting
N/A
500000
Europe
ICI, Immune checkpoint inhibitors
Groupe Hospitalier Pitie-Salpetriere
Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Pericarditis, Vasculitis
01/25
01/25
DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Recruiting
N/A
20605
Europe
lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib
Pfizer
Non-Small Cell Lung Cancer
02/25
02/25
IMMUNOVASC, NCT05655663: Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer

Recruiting
N/A
30
Europe
Vascular investigation
Centre Henri Becquerel
Head and Neck Cancer, Lung Cancer
02/25
12/25
NCT03409016: Biomarkers of Immune-Related Toxicity

Recruiting
N/A
69
US
Blood Testing
University of Colorado, Denver, Cancer League of Colorado
Cancer, Metastatic Cancer
05/25
05/27
NCT05573282: Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

Recruiting
N/A
50
RoW
Regorafenib combine with ICIs
Sun Yat-sen University
Hepatocellular Carcinoma
06/25
01/26
KOSMOS-II, NCT05525858: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting
N/A
1000
RoW
Alectinib, Alecensa, Atezolizumab, Tecentriq, Erlotinib, Tarceva, Trastuzumab + Pertuzumab, Herceptin + Perjeta, Trastuzumab emtansine, Kadcyla, Vemurafenib, Zelboraf, Bevacizumab + Erlotinib, Avastin + Tarceva, Entrectinib, Rozlytrek, Pralsetinib, Gavreto
Seoul National University Bundang Hospital, Korean Cancer Study Group, Roche Pharma AG
Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
09/25
09/25
IMMUNOCELL, NCT05044676: Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma

Recruiting
N/A
120
Europe
patients with hepatocellular carcinoma
Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
09/25
09/27
IMMUNOGLYPIC, NCT05263830: Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

Recruiting
N/A
120
Europe
Quantitative assay of GlypicanPC-3
Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
09/25
09/27
TIP, NCT05831553: in Patients Affected by Metastatic TNBC

Recruiting
N/A
100
Europe
Tissue Immune Profile
Fondazione per la Medicina Personalizzata, University of Roma La Sapienza
Metastatic Triple-negative Breast Cancer
09/25
09/25
LATINA, NCT04158258: A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active, not recruiting
N/A
2907
RoW
Bevacizumab, Avastin, Trastuzumab, Herceptin, Ado-trastuzumab emtamsine, Kadcyla, Pertuzumab, Perjeta, Atezolizumab, Tecentriq, Capecitabine
Hoffmann-La Roche, Latin American Cooperative Oncology Group
Breast Cancer
11/25
11/25
NCT05991206: A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

Recruiting
N/A
200
RoW
Hunan Province Tumor Hospital
NSCLC
12/25
08/26
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Recruiting
N/A
48
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital
Carcinoma, Hepatocellular
12/25
12/25
HOLMBRAVE, NCT05705791: Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma

Recruiting
N/A
33
Europe
QuiremSpheres, 166Holmium microspheres, 166Holmium SIRT
Gustave Roussy, Cancer Campus, Grand Paris
Hepatocellular Carcinoma
02/26
08/26
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Recruiting
N/A
456
RoW
Atezolizumab, Bevacizumab, Surgery
Jia Fan
Venous Thrombosis
08/27
03/28
NCT05834413: Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

Not yet recruiting
N/A
367
RoW
chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo
Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital
Lung Cancer
06/26
06/26
IMreal, NCT03782207: A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

Active, not recruiting
N/A
3040
Europe, RoW
Atezolizumab, Tecentriq
Hoffmann-La Roche
Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma
07/26
07/26
REFINE-IO, NCT06117891: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Recruiting
N/A
300
Europe, US, RoW
Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab,
Bayer
Unresectable Hepatocellular Carcinoma
11/26
02/27
MIMIR-mTNBC, NCT05742269: Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer

Recruiting
N/A
64
Europe
89Zr-atezolizumab PET/CT
Karolinska University Hospital
Metastatic Triple-Negative Breast Carcinoma
12/26
05/27
ChiCTR2300069317: Exploratory study of Clostridium butyricum combined with atezolizumab in adjuvant treatment of resectable non-small cell lung caner

Recruiting
N/A
20
 
Clostridium Butyricum Tablets
Peking University Cancer Hospital & Institute; Peking University Cancer Hospital & Institute, Hangzhou Yidian Information Technology Co., Ltd.; LinkDoc (Beijing) Co., Ltd.
resectable non-small cell lung caner
 
 
PICASSO, NCT05797493: Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Recruiting
N/A
100
Europe
Atezolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Small Cell Lung Cancer
06/27
06/27
NCT04663438: Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC

Recruiting
N/A
300
RoW
Chemotherapy Drugs, Cancer
Peking Union Medical College Hospital, Beijing Hospital, China-Japan Friendship Hospital, Beijing Chest Hospital, Beijing Chao Yang Hospital
Extensive-stage Small Cell Lung Cancer
12/20
05/21
HEPATOFIT, NCT04730388: ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or

Not yet recruiting
N/A
100
NA
University Hospital, Brest
Advanced Hepatocellular Carcinoma
01/22
01/22
NCT04355806: Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Not yet recruiting
N/A
160
RoW
PD-1/PD-L1 inhibitors, PD-1/PD-L1 blockades, PD-1 monoclonal antibodies, PD-L1 monoclonal antibodies, Inactivated trivalent influenza vaccine, Flu Vaccines, Influenza Virus Vaccines, Influenza Vaccine, Trivalent, Vaccine, Trivalent Influenza, Flu Shot
Shanghai Pulmonary Hospital, Shanghai, China, The University of Hong Kong
Non Small Cell Lung Cancer, Influenza Vaccine
12/22
05/23
 

Download Options